Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 1,317	$ 314	$ 2,276	$ 1,006
In-process research and development	0	30,117	0	30,117
General and administrative	2,255	2,427	5,184	3,688
Total operating expenses	3,572	32,858	7,460	34,811
Loss from operations	(3,572)	(32,858)	(7,460)	(34,811)
Other income (expense):
Gain on forgiveness of PPP loan	0	0	0	279
Loss on issuance of secured debt	0	0	0	(686)
Gain on change in fair value of warrant liability	1,225	5,133	2,018	5,175
Gain on change in fair value of share liability	0	73	0	73
Interest expense	(5)	(655)	(6)	(2,367)
Other income	8	16	9	16
Loss on issuance of LBS Series 1 Preferred Stock	0	(1,881)	0	(1,881)
Loss on issuance of warrants	0	(1,574)	(1,110)	(1,574)
Total other income (expense)	1,228	1,112	911	(965)
Net loss	$ (2,344)	$ (31,746)	$ (6,549)	$ (35,776)
Loss per share:
Basic net loss per common share	$ (0.12)	$ (3.59)	$ (0.36)	$ (6.17)
Diluted net loss per common share	$ (0.12)	$ (4.10)	$ (0.36)	$ (6.96)
Weighted average shares used in computing loss per share:
Weighted average shares used in calculating basic loss per share	20,294,652	8,831,517	18,281,788	5,803,010
Weighted-average shares outstanding	20,294,652	8,984,198	18,281,788	5,879,351
Net loss attributable to common shares - basic	$ (2,344)	$ (31,746)	$ (6,549)	$ (35,776)
Net loss attributable to common shares - diluted	$ (2,344)	$ (36,865)	$ (6,549)	$ (40,895)